Evidence map›Paper›PMID 25485012›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2014

Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey.

Philippe D Violette, Suzanne Kamel-Reid, Gail E Graham, M Neil Reaume, Michael A Jewett, Melanie Care, Joan Basiuk, Stephen E Pautler

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
  3. Article
  4. Clinical predictors of a positive test result in patients undergoing genetic evaluation for a hereditary kidney cancer syndrome.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Philippe D VioletteDivision of Urology, Department of Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON;
Suzanne Kamel-ReidMolecular Diagnostics, Department of Pathology, University Health Network, Toronto, ON;
Gail E GrahamEastern Ontario Regional Genetics Program, Children's Hospital of Eastern Ontario and the University of Ottawa, Ottawa, ON;
M Neil ReaumeDivision of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, ON;
Michael A JewettDepartment of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON;
Melanie CareDepartment of Molecular Genetics, University Health Network, Toronto, ON;
Joan BasiukKidney Cancer Research Network of Canada, Toronto, ON;
Stephen E PautlerDivision of Urology, Department of Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON; ; Division of Surgical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON.
University Health Network · CAUniversity of Ottawa · CAWestern University · CAAlberta Kidney Disease Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductonTreatment of hereditary renal cell carcinoma (HRCC) requires a multidisciplinary approach that may involve medical oncologists, geneticists, genetic counsellors, and urologists. The objective of our survey was to obtain current and representative information about the use and perceived importance of genetic testing for HRCC in Canada.

methodsA self-administered web-based survey was provided to Canadian medical oncologists, geneticists, genetic counsellors, and urologists in collaboration with their respective associations. The survey was created through an iterative process in consultation with the Kidney Cancer Research Network of Canada and contained both quantitative and qualitative components. The survey was designed to be exploratory and results were compared across regions.

resultsThe overall response was low (6.6%). Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. Of the respondents, 62.7% described their practice as academic, and 37.3% described it as non-academic. Non-academic respondents tended to refer for genetic counselling less frequently than academic (48.6% vs. 67.2%). Most respondents believed that genetic testing for HRCC was available (82.8%), although 47.7% did not know which tests were available. This observation was consistent across provinces. Testing for Von Hippel-Lindau syndrome was given the highest priority among respondents. Limited provider knowledge, clinical guidelines, institutional funding, access, and poor coordination between disciplines were cited as barriers to testing.

interpretationThere is a need to increase provider knowledge of genetic testing for HRCC. These findings support the development of practice guidelines and national strategies to improve coordination of specialists and access to genetics services. Limitations of the present study include low survey response which did not allow for inferential analysis by geographic region or respondent specialty.

Identifiers

PMID25485012
PMCPMC4250249
OpenAlexW1985462868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.